sorafenib has been researched along with lopinavir in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (lopinavir) | Trials (lopinavir) | Recent Studies (post-2010) (lopinavir) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 2,383 | 499 | 1,358 |
| Protein | Taxonomy | sorafenib (IC50) | lopinavir (IC50) |
|---|---|---|---|
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.7 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 9.12 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.035 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 8.5114 | |
| Protease | Human immunodeficiency virus 1 | 0.025 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 7.6 | |
| Protease | Human immunodeficiency virus 1 | 0.0175 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Abou-El-Naga, IF; Fawzy Hussien Mogahed, NM; Mady, RF | 1 |
1 review(s) available for sorafenib and lopinavir
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
2 other study(ies) available for sorafenib and lopinavir
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
In vitro effectivity of three approved drugs and their synergistic interaction against Leishmania infantum.
Topics: Auranofin; Drug Combinations; Drug Synergism; Leishmania infantum; Lopinavir; Parasitology; Ritonavir; Sorafenib | 2020 |